John R Burnett

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 12

Top Topics

Low Density Lipoprotein

Cardiovascular Disease

Top Venues

Expert opinion on investigational drugs

European journal of human genetics : EJHG

Annals of clinical biochemistry

Expert opinion on pharmacotherapy

This page only lists publications with an associated author ORCID identifier.

Publications

Amanda J Hooper, Xuan L Tang, John R Burnett
VERVE-101, a CRISPR base-editing therapy designed to permanently inactivate hepatic PCSK9 and reduce LDL-cholesterol. Expert opinion on investigational drugs (2024)
P Mihika S Fernando, Amanda J Hooper, John R Burnett
Lepodisiran, an siRNA targeting lipoprotein(a) for the potential future treatment of cardiovascular disease. Expert opinion on investigational drugs (2024)
Amanda J Hooper, P Mihika S Fernando, John R Burnett
Potential of muvalaplin as a lipoprotein(a) inhibitor. Expert opinion on investigational drugs 33 (1) (2024)
P Mihika S Fernando, Amanda J Hooper, John R Burnett
Lepodisiran, an siRNA targeting lipoprotein(a) for the potential future treatment of cardiovascular disease. Expert opinion on investigational drugs (2024)
P Mihika S Fernando, Amanda J Hooper, John R Burnett
Lepodisiran, an siRNA targeting lipoprotein(a) for the potential future treatment of cardiovascular disease. Expert opinion on investigational drugs 33 (7) (2024)
Amanda J Hooper, Xuan L Tang, John R Burnett
VERVE-101, a CRISPR base-editing therapy designed to permanently inactivate hepatic PCSK9 and reduce LDL-cholesterol. Expert opinion on investigational drugs 33 (8) (2024)
Amanda J Hooper, P Mihika S Fernando, John R Burnett
Potential of muvalaplin as a lipoprotein(a) inhibitor. Expert opinion on investigational drugs (2024)
Amanda J Hooper, P Mihika S Fernando, John R Burnett
Potential of muvalaplin as a lipoprotein(a) inhibitor. Expert opinion on investigational drugs 33 (1) (2024)
Amanda J Hooper, Damon A Bell, John R Burnett
Olezarsen, a liver-directed APOC3 ASO therapy for hypertriglyceridemia. Expert opinion on pharmacotherapy (2024)
V Thadchanamoorthy, M B Kavinda Chandimal Dayasiri, S I Majitha, Amanda J Hooper, John R Burnett
Homozygous autosomal recessive hypercholesterolaemia in a South Asian child presenting with multiple cutaneous xanthomata. Annals of clinical biochemistry 58 (2) (2020)
Amanda J Hooper, Sally P A McCormick, Robert A Hegele, John R Burnett
Clinical utility gene card for: Tangier disease. European journal of human genetics : EJHG 25 (7) (2017)
Amanda J Hooper, Damon A Bell, Robert A Hegele, John R Burnett
Clinical utility gene card for: Sitosterolaemia. European journal of human genetics : EJHG 25 (4) (2016)